Largest Prospective Study in General-Risk Pregnancies Strengthens Evidence for cfDNA Fetal Risk Assessment as a Primary Screen for Recessive Conditions

Study of more than 2,200 pregnant carriers demonstrates strong clinical performance in the intended-use, general-risk population, with outcomes available for more than 98% of eligible cfDNA results MENLO PARK, Calif., Aug. 18, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced publication of A Prospective, Multi-Site Study of Performance of Cell-Free DNA Testing for Recessive Conditions in a Large, General-Risk Pregnancy Population in The Green Journal.

PRNewsWire • Aug 18, 2026

BillionToOne: A Softer Quarter After Heightened Expectations

BillionToOne experienced a sharp post-earnings sell-off despite maintaining full-year guidance and strong year-over-year revenue growth. Second quarter results showed slowing sequential growth, softer average selling prices, and significant margin compression versus Q1. The company trades at ~10x sales, a premium to May levels, with the growth story intact but near-term valuation less attractive.

Seeking Alpha • Aug 7, 2026

Why BillionToOne Plummeted 36%, Leading A Medtech Sell-Off

Medical research stocks took a bath Thursday, helped by BillionToOne's second-quarter report, featuring a beat but no guidance raise.

Investors Business Daily • Aug 6, 2026

Billiontoone Q2 Earnings Call Highlights

Billiontoone NASDAQ: BLLN reported second-quarter 2026 revenue growth of 64% year over year, driven by higher testing volumes and average selling prices across its prenatal and oncology businesses. The molecular diagnostics company also posted positive operating income and free cash flow while reiterating its full-year revenue outlook.

MarketBeat • Aug 5, 2026

BillionToOne Reports Second Quarter 2026 Results and Reiterates 2026 Revenue Guidance

MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the second quarter ended June 30, 2026 and reiterated guidance for full year 2026.

GlobeNewsWire • Aug 5, 2026

BillionToOne (BLLN) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for BillionToOne (BLLN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • Aug 6, 2026

Read Between These Lines As Eli Lilly, Hot IPO And More Face Key Test

As stocks like Eli Lilly, Twilio, Hinge Health and more move ahead of earnings report, pay attention to these chart lines.

Investors Business Daily • Aug 3, 2026

BillionToOne: The Guidance Looks Conservative, The Price Does Not

BillionToOne is a GAAP-profitable molecular diagnostics IPO with a scalable platform and rapid revenue growth. BLLN's QCT technology improves DNA test accuracy, enabling strong prenatal market share and promising oncology expansion. Integration with Epic and major insurance contracts position BLLN for accelerated adoption and revenue upside beyond conservative guidance.

Seeking Alpha • Jul 29, 2026

BillionToOne Appoints Ethan Dmitrovsky, MD, as Chief Medical Officer, Oncology, to Lead Medical Strategy for Northstar

Renowned physician-scientist, former Director of Frederick National Laboratory, and one of the nation's most accomplished leaders in oncology joins BillionToOne to advance Northstar's role in guiding real treatment decisions MENLO PARK, Calif., July 20, 2026 /PRNewswire/ -- BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the appointment of Ethan Dmitrovsky, MD, one of the most accomplished and influential physician leaders in oncology, as Chief Medical Officer, Oncology.

PRNewsWire • Jul 20, 2026

BillionToOne to Report Second Quarter 2026 Financial Results on August 5, 2026

MENLO PARK, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for the second quarter ended June 30, 2026 after the market close on Wednesday, August 5, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same day.

GlobeNewsWire • Jul 15, 2026